Lineage Cell Therapeutics, Inc.: stock overview

LCTXAMEXHealthcare · Biological Products, (No Diagnostic Substances)

Price

$0.77

November 20, 2026Market cap $192M

What Ploutos Investor adds for Lineage Cell Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 22% since Nov 12, 2026, when the 10-Q these figures come from was filed ($0.99 then, $0.77 on Nov 20, 2026). The figures date from before that move.10-Q
  • Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.

In short

Lineage Cell Therapeutics had revenue of $11M over the last 12 months and net income of $1.8M, a net margin of 16.2%. Revenue grew by 51.5% a year on average over the last 5 years. It holds more cash than debt, by $45M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 20, 2026.

Its SEC filings
Market cap
$192M
249M shares
P/E
–
Revenue, 12 months
$11M
+51.5% a year over 5 years
Net margin
16.2%

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+27.6% a year over 2 years

Fiscal years in figures

LCTX's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $206M
$192M
Enterprise value 
$147M
P/E 
–
EV / EBIT 
–
EV / Revenue 
13.6
P/B 3-year median: 3.2
2.9
FCF yield 3-year median: -14.2%
–
Earnings yield 3-year median: -16.8%
–

Profitability

Operating margin 
-280.3%
Net margin 3-year median: -240.2%
16.2%
ROIC 
-48.3%
ROIC, 5-year average 
-29.7%
ROE 
3.5%

Growth

Revenue, yearly change 
+53.2%
EPS, yearly change 
–
FCF, yearly change 
–
Revenue, average a year 
+51.5%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$45M
Total debt 
$2.0M
Of which operating leases 
$2.0M
Net cash 
$45M
Net debt / EBITDA 
–
Interest cover 
–
Current ratio 
5.96

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+9.1%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Lineage Cell Therapeutics, Inc.
Exchange
AMEX
Industry (SIC)
2836 · Biological Products, (No Diagnostic Substances)
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
249M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Lineage Cell Therapeutics's filings show?

These are Lineage Cell Therapeutics's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about LCTX

Didn't find what you were looking for?

Ask us
What is LCTX's market cap?

Lineage Cell Therapeutics, Inc.'s market cap is $192M, at a price of $0.77 on November 20, 2026 and 249M shares.

How much revenue does LCTX have?

Lineage Cell Therapeutics had revenue of $11M over the last 12 months. Over the last 5 years it changed by +51.5% a year on average.

Does LCTX pay a dividend?

No. Lineage Cell Therapeutics paid no regular dividend over the last 12 months.

Where do the figures come from?

From Lineage Cell Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.